Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of specialty pharmaceutical company BioSante Pharmaceuticals
So what: Sexual dysfunction drug LibiGel lost out to placebo in two FDA trials. BioSante still has other sexual-health and anti-cancer drugs approved and/or under development, but investors placed a lot of hope and faith in LibiGel -- and that dream is dead now.
Now what: This was supposed to be the female version of Viagra, which has made untold billions for Pfizer
Interested in more info about BioSante Pharmaceuticals? Click here to add it to My Watchlist.